Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleNeurology

First-in-Human Assessment of 11C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer

Mika Naganawa, Nabeel Nabulsi, Shannan Henry, David Matuskey, Shu-Fei Lin, Lawrence Slieker, Adam J. Schwarz, Nancy Kant, Cynthia Jesudason, Kevin Ruley, Antonio Navarro, Hong Gao, Jim Ropchan, David Labaree, Richard E. Carson and Yiyun Huang
Journal of Nuclear Medicine April 2021, 62 (4) 553-560; DOI: https://doi.org/10.2967/jnumed.120.246967
Mika Naganawa
1PET Center, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nabeel Nabulsi
1PET Center, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shannan Henry
1PET Center, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Matuskey
1PET Center, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shu-Fei Lin
1PET Center, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence Slieker
2Eli Lilly and Company, Indianapolis, Indiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam J. Schwarz
2Eli Lilly and Company, Indianapolis, Indiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy Kant
2Eli Lilly and Company, Indianapolis, Indiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cynthia Jesudason
2Eli Lilly and Company, Indianapolis, Indiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin Ruley
2Eli Lilly and Company, Indianapolis, Indiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Navarro
2Eli Lilly and Company, Indianapolis, Indiana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong Gao
1PET Center, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jim Ropchan
1PET Center, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Labaree
1PET Center, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard E. Carson
1PET Center, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yiyun Huang
1PET Center, Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure1
    • Download figure
    • Open in new tab
    • Download powerpoint
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    Molecular structure of 11C-LSN3172176.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    (A and B) Mean ± SD of plasma parent fraction (A) and metabolite-corrected input function (B) in test and retest scans of 11C-LSN3172176. (C and D) Plasma parent fraction (C) and metabolite-corrected input function (D) in baseline and blocking scans.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    MR and coregistered typical PET images of 11C-LSN3172176 under test and retest conditions in one subject and under baseline and blocking conditions in another subject. PET images were summed from 30 to 60 min after injection.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Time–activity curves of 11C-LSN3172176 in baseline (A) and blocking (B) scans and fits with 1TC, 2TC, SRTM, and SRTM2. CER = cerebellum; FRO = frontal cortex; PUT = putamen; THA = thalamus.

  • FIGURE 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 5.

    Lassen plot of mean regional 1TC VT of 11C-LSN3172176 (n = 4). Error bar shows SEM. Ventral striatum (VST), putamen (PUT), caudate (CAU), pallidum (PAL), and cerebellum (CER) are shown as open circles, and other regions are shown as closed circles.

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

    Subject Information and PET Scan Parameters

    ParameterTest (n = 6)Retest (n = 6)Baseline (n = 5)Blocking (n = 5)
    Age (y)38 ± 1043 ± 2
    Body weight (kg)81 ± 1688 ± 13
    Injected dose (MBq)559 ± 109584 ± 152601 ± 74579 ± 141
    Specific activity at injection (MBq/nmol)452 ± 83400 ± 100139 ± 42158 ± 31
    Injected mass (μg/kg)0.006 ± 0.0020.008 ± 0.0040.021 ± 0.0080.017 ± 0.006
    • Data are mean ± SD. Age and weight are for test and retest groups combined and for baseline and blocking groups combined.

    • View popup
    TABLE 2

    Binding Parameters from Test–Retest Study of 11C-LSN3172176

    1TC VT (mL/cm3) (n = 6)1TC BPND (n = 6)SRTM2 BPND (n = 6)
    RegionTestRetestMinimum scan time (min)TestRetestMinimum scan time (min)TestRetest
    Ventral striatum48.5 (16%)48.9 (20%)508.87 (12%)8.69 (17%)508.60 (17%)8.00 (14%)
    Putamen38.6 (22%)39.3 (22%)606.82 (20%)6.74 (18%)606.63 (23%)6.31 (16%)
    Caudate30.2 (19%)30.4 (20%)605.13 (15%)4.98 (14%)704.97 (19%)4.64 (12%)
    Amygdala28.8 (21%)28.8 (18%)404.80 (14%)4.67 (8%)504.62 (20%)4.3 (12%)
    Temporal cortex27.4 (15%)27.9 (14%)604.56 (10%)4.52 (10%)704.41 (11%)4.25 (8%)
    Occipital cortex26.7 (16%)27.3 (14%)604.42 (9%)4.41 (9%)704.28 (10%)4.17 (8%)
    Parietal cortex25.5 (16%)26.1 (13%)604.18 (9%)4.16 (9%)604.04 (9%)3.94 (8%)
    Frontal cortex24.4 (17%)24.7 (15%)603.96 (14%)3.88 (12%)703.83 (14%)3.67 (10%)
    Hippocampus17.5 (18%)18.0 (15%)702.55 (16%)2.58 (16%)802.48 (21%)2.42 (17%)
    Globus pallidus16.4 (24%)16.6 (24%)402.31 (25%)2.27 (24%)402.26 (28%)2.15 (23%)
    Centrum semiovale9.0 (16%)9.4 (15%)300.82 (16%)0.85 (13%)400.77 (16%)0.78 (17%)
    Thalamus8.7 (19%)9.0 (19%)300.76 (27%)0.76 (20%)300.75 (28%)0.75 (19%)
    Cerebellum4.9 (12%)5.1 (14%)30
    • Data are percentage coefficient of variation followed by intersubject variability in parentheses.

    • View popup
    TABLE 3

    Binding Parameters from Baseline-Blocking Study of 11C-LSN3172176

    1TC VT (mL/cm3)1TC BPND
    RegionBaseline (n = 5)Blocking (n = 4)Baseline (n = 5)Blocking (n = 4)
    Ventral striatum44.6 (10%)34.0 (12%)7.82 (8%)5.68 (7%)
    Putamen37.2 (9%)26.6 (11%)6.37 (7%)4.25 (11%)
    Caudate29.7 (19%)21.2 (24%)4.85 (14%)3.14 (19%)
    Amygdala27.4 (12%)18.9 (15%)4.44 (16%)2.71 (10%)
    Temporal cortex24.7 (9%)16.5 (14%)3.89 (8%)2.25 (10%)
    Occipital cortex23.8 (7%)14.9 (11%)3.71 (7%)1.94 (10%)
    Parietal cortex23.1 (7%)14.9 (13%)3.59 (11%)1.94 (14%)
    Frontal cortex22.5 (12%)14.6 (15%)3.45 (11%)1.88 (13%)
    Hippocampus17.7 (11%)12.4 (13%)2.51 (15%)1.44 (13%)
    Globus pallidus15.6 (9%)12.6 (17%)2.12 (24%)1.51 (35%)
    Centrum semiovale8.7 (14%)6.8 (14%)0.72 (28%)0.34 (40%)
    Thalamus9.4 (13%)7.3 (9%)0.86 (12%)0.43 (12%)
    Cerebellum5.1 (11%)5.1 (10%)
    • Data are percentage coefficient of variation followed by intersubject variability in parentheses.

    • View popup
    TABLE 4

    Occupancy by Scopolamine and VND 11C-LSN3172176

    One-occupancy modelTwo-occupancy model
    SubjectOccupancy (%)VND (mL/cm3)Nonstriatum occupancy (%)Striatum occupncy (%)VND (mL/cm3)
    147 (7%)3.87 (15%)52 (4%)41 (5%)4.17 (5%)
    234 (15%)5.24 (20%)44 (8%)27 (15%)6.01 (6%)
    331 (13%)4.49 (21%)36 (7%)24 (19%)5.51 (8%)
    439 (7%)4.92 (13%)43 (4%)33 (8%)5.19 (6%)
    Mean ± SD4.63 ± 0.595.22 ± 0.77
    • Data are best-fit values using nonlinear analysis, followed by relative percentage SE in parentheses.

    • View popup
    TABLE 5

    Test–Retest Reproducibility Parameters of 11C-LSN3172176

    1TC VT (mL/cm3) (n = 6)1TC BPND (n = 6)SRTM2 BPND (n = 6)
    RegionaTRVTRVICCaTRVTRVICCaTRVTRVICC
    Ventral striatum5%0% ± 7%0.927%3% ± 8%0.878%7% ± 6%0.83
    Putamen2%−2% ± 2%0.994%1% ± 4%0.989%4 ± 9%0.84
    Caudate1%0% ± 1%1.004%3% ± 3%0.968%6 ± 8%0.79
    Amygdala3%−1% ± 4%0.996%2% ± 7%0.8111%6 ± 12%0.67
    Temporal cortex3%−2% ± 3%0.984%1% ± 5%0.927%4 ± 8%0.61
    Occipital cortex4%−3% ± 5%0.936%0% ± 7%0.728%2 ± 10%0.34
    Parietal cortex5%−2% ± 6%0.926%0% ± 8%0.678%3 ± 11%0.35
    Frontal cortex4%−1% ± 4%0.976%2% ± 7%0.896%4 ± 7%0.78
    Hippocampus4%−4% ± 4%0.966%−1% ± 8%0.909%1 ± 11%0.87
    Globus pallidus4%−2% ± 5%0.986%2% ± 9%0.957%4 ± 7%0.94
    Centrum semiovale4%−4% ± 3%0.947%−4% ± 8%0.876%−1 ± 8%0.91
    Thalamus4%−3% ± 4%0.9710%−1% ± 12%0.9111%−1% ± 13%0.88
    Cerebellum4%−3% ± 3%0.96
    • aTRV = absolute TRV; ICC = intraclass correlation coefficient.

Additional Files

  • Figures
  • Tables
  • HTML Page - index.htslp

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (4)
Journal of Nuclear Medicine
Vol. 62, Issue 4
April 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
First-in-Human Assessment of 11C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
First-in-Human Assessment of 11C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer
Mika Naganawa, Nabeel Nabulsi, Shannan Henry, David Matuskey, Shu-Fei Lin, Lawrence Slieker, Adam J. Schwarz, Nancy Kant, Cynthia Jesudason, Kevin Ruley, Antonio Navarro, Hong Gao, Jim Ropchan, David Labaree, Richard E. Carson, Yiyun Huang
Journal of Nuclear Medicine Apr 2021, 62 (4) 553-560; DOI: 10.2967/jnumed.120.246967

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
First-in-Human Assessment of 11C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer
Mika Naganawa, Nabeel Nabulsi, Shannan Henry, David Matuskey, Shu-Fei Lin, Lawrence Slieker, Adam J. Schwarz, Nancy Kant, Cynthia Jesudason, Kevin Ruley, Antonio Navarro, Hong Gao, Jim Ropchan, David Labaree, Richard E. Carson, Yiyun Huang
Journal of Nuclear Medicine Apr 2021, 62 (4) 553-560; DOI: 10.2967/jnumed.120.246967
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Linking Brain Entropy to Molecular and Cellular Architecture in Psychosis
  • Connectome-based brain fingerprints predict early cognitive decline in Parkinsons patients with minor hallucinations
  • An engine for systematic discovery of cause-effect relationships between brain structure and function
  • Geometric influences on the regional organization of the mammalian brain
  • Brain maps of general cognitive function and spatial correlations with neurobiological cortical profiles
  • Mapping the Microstructure of Human Cerebral Cortex In Vivo with Diffusion MRI
  • Mapping neuropeptide signaling in the human brain
  • A replicable and generalizable neuroimaging-based indicator of pain sensitivity across individuals
  • Concurrent assessment of neurometabolism and brain hemodynamics to comprehensively characterize the functional brain response to psychotropic drugs: an S-ketamine study
  • Benchmarking methods for mapping functional connectivity in the brain
  • Controlling the human connectome with spatially diffuse input signals
  • Integrating brainstem and cortical functional architectures
  • The biological role of local and global fMRI BOLD signal variability in human brain organization
  • Resting state changes in aging and Parkinsons disease are shaped by underlying neurotransmission - a normative modeling study
  • Transitions between cognitive topographies: contributions of network structure, neuromodulation, and disease
  • Multimodal, multiscale connectivity blueprints of the cerebral cortex
  • Whole-brain modeling explains the context-dependent effects of cholinergic neuromodulation
  • PET Imaging of Cholinergic Neurotransmission in Neurodegenerative Disorders
  • Molecular and connectomic vulnerability shape cross-disorder cortical abnormalities
  • Mapping neurotransmitter systems to the structural and functional organization of the human neocortex
  • neuromaps: structural and functional interpretation of brain maps
  • Correspondence between gene expression and neurotransmitter receptor and transporter density in the human brain
  • Google Scholar

More in this TOC Section

Neurology

  • Dopamine D1 Receptor Agonist PET Tracer Development: Assessment in Nonhuman Primates
  • Hypermetabolism on Pediatric PET Scans of Brain Glucose Metabolism: What Does It Signify?
  • TauIQ: A Canonical Image Based Algorithm to Quantify Tau PET Scans
Show more Neurology

Translational

  • Quantitative Total-Body Imaging of Blood Flow with High-Temporal-Resolution Early Dynamic 18F-FDG PET Kinetic Modeling
  • [99mTc]Tc-MY6349 Probe for Trop2-Targeted SPECT Imaging: From Preclinical to Pilot Clinical Study
  • Imaging Diverse Pathogenic Bacteria In Vivo with 18F-Fluoromannitol PET
Show more Translational

Similar Articles

Keywords

  • muscarinic acetylcholine receptor 1
  • PET
  • test–retest reproducibility
  • brain imaging
  • scopolamine
SNMMI

© 2025 SNMMI

Powered by HighWire